SGSebastien R. G. Galan

Sebastien R. G. Galan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sebastien R. G. Galan has a total of 200 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia

    by Thomas J. Cogswell, Laia Josa-Culleré, David Zimmer, Sébastien R. G. Galan, Morgan Jay-Smith, Kate S. Harris, Carole J. R. Bataille, Thomas R. Jackson, Douzi Zhang, Stephen G. Davies, et al.

    The optimisation of a class of AML differentiation agents is described to show improved potency, solubility and stability, reduced off target toxicity, and tumour regression in a murine model in vivo.


  • Open Access

    The Minimum Protein Staple? – Towards ‘bio’-Baldwin's rules via inter-phosphosite linking in the MEK1 activation loop

    by Sébastien R. G. Galan, Ritu Raj, Dimitrios Mamalis, Lyn H. Jones, Shabaz Mohammed, Benjamin G. Davis

    In small molecule organic chemistry, the heuristic insight into ring-forming processes that was enabled by Baldwin's rules some 50 years ago proved a step-change in the role of mechanistically guided synthesis. It created a lens upon and marker of fundamental stereoelectronic and conformation-guided chemical processes. However, despite the widespread role of stereoelectronics and conformational control in Biology, no equivalent coherent exploitation of trapped, ring-forming processes yet exists in biomolecules. In the development of a minimal ring-closing process in intact proteins that might prove suitable in a coherent rule-set, we have tested endo-trig ring-closing conjugate thioether lanthionine (Lan) –CH2–S–CH2- formation as a limiting cyclization. Spontaneous Lan formation in proteins is rare if not non-existent and when found in natural product cyclic peptides it requires the mediation of corresponding biosynthetic enzymes as well as productive reactive conformations to guide it. Here, we show that within a conformationally flexible and functionally important protein loop – the MAPK kinase phosphorylation-targeted activation loop – Lan ring-closing is possible. Ring-closing proves to be critically dependent on the location of a trig electrophilic site in just one of two regioisomeric potential precursors to allow phosphosite-to-phosphosite ‘stapling’. This first example of spontaneous protein thioether ring-closing/‘stapling’ and its accessibility from just one precursor (despite the potential for both to form an identical ‘staple’) now reveals the potential for Lan formation not only as an accessible form of minimal stapling in proteins but also as an exquisitely sensitive probe of associated protein geometries. We suggest that the use of this (as well as the development of other such, intramolecular protein traps that are dependent on inherent protein-controlled reactivity rather than forced crosslinking) may allow the broader trapping and mapping of relevant, even minor, protein states. In this way, protein ring formation may enable a form of extended ‘bio-Baldwin's rules' that help to delineate relevant protein conformational space.


  • Open Access

    Pilot Study to Quantify Palladium Impurities in Lead-like Compounds Following Commonly Used Purification Techniques

    by Maria Chatzopoulou, Katrina S. Madden, Liam J. Bromhead, Christopher Greaves, Thomas J. Cogswell, Solange Da Silva Pinto, Sébastien R. G. Galan, Irene Georgiou, Matthew S. Kennedy, Alice Kennett, et al.

    Palladium-catalyzed reactions are among the most commonly used procedures in organic synthesis. The products have a range of uses, including as intermediates in total synthesis and as screening compounds for drug discovery or agrochemical projects. Despite the known and potentially deleterious effects of low-level metal impurities in biological assays, the quantification of metal remaining in reaction products to verify the effective removal of the transition element is rarely reported. Using palladium as an exemplar, we describe a pilot study that for the first time quantifies residual metal levels in reaction products following increasingly rigorous purification protocols. Our results demonstrate that significant levels of residual palladium can remain in isolated reaction products following chromatographic purification, and only by using a subsequent metal scavenging step are they reliably reduced to a low level. Finally, we provide a set of simple guidelines that should minimize the potential for issues associated with residual palladium in reaction products.


  • Imaging Mutant Huntingtin Aggregates: Development of a Potential PET Ligand

    by Longbin Liu, Michael E. Prime, Matt R. Lee, Vinod Khetarpal, Christopher J. Brown, Peter D. Johnson, Patricia Miranda-Azpiazu, Xuemei Chen, Daniel Clark-Frew, Samuel Coe, et al.

    Mutant huntingtin (mHTT) protein carrying the elongated N-terminal polyglutamine (polyQ) tract misfolds and forms protein aggregates characteristic of HD pathology. A high-affinity ligand specific for mHTT aggregates could serve as a positron emission tomography (PET) imaging biomarker for HD therapeutic development and disease progression. With a strategy to identify compounds with binding affinity for polyQ aggregates, we embarked on systematic structural activity studies; lead optimization of aggregate-binding affinity, unbound fractions in brain, permeability and low efflux culminated in the discovery of compound 1, which exhibited target engagement in autoradiography (ARG) studies in brain slices from HD mouse models and post-mortem human HD samples. PET imaging studies with 11C-labelled 1 in both HD mice and WT nonhuman primates (NHPs) demonstrated that the right-hand side labelled ligand [11C]-1R (CHDI-180R) is a suitable PET tracer for imaging of mHTT aggregates. [11C]-1R is now being advanced to human trials as a first-in-class HD PET radiotracer.


  • Characterisation of utrophin modulator SMT C1100 as a non-competitive inhibitor of firefly luciferase

    by Isabel V.L. Wilkinson, Jessica K. Reynolds, Sébastien R.G. Galan, Aini Vuorinen, Adam J. Sills, Elisabete Pires, Graham M. Wynne, Francis X. Wilson, Angela J. Russell


  • Open Access

    Synthesis of modified proteins via functionalization of dehydroalanine

    by Jitka Dadová, Sébastien Rg Galan, Benjamin G Davis


  • Post-translational site-selective protein backbone α-deuteration

    by Sébastien R. G. Galan, James R. Wickens, Jitka Dadova, Wai-Lung Ng, Xinglong Zhang, Robert A. Simion, Robert Quinlan, Elisabete Pires, Robert S. Paton, Stephen Caddick, et al.

    Isotopic replacement has long-proven applications in small molecules. However, applications in proteins are largely limited to biosynthetic strategies or exchangeable (for example, N–H/D) labile sites only. The development of postbiosynthetic, C–1H → C–2H/D replacement in proteins could enable probing of mechanisms, among other uses. Here we describe a chemical method for selective protein α-carbon deuteration (proceeding from Cys to dehydroalanine (Dha) to deutero-Cys) allowing overall 1H→2H/D exchange at a nonexchangeable backbone site. It is used here to probe mechanisms of reactions used in protein bioconjugation. This analysis suggests, together with quantum mechanical calculations, stepwise deprotonations via on-protein carbanions and unexpected sulfonium ylides in the conversion of Cys to Dha, consistent with a ‘carba-Swern’ mechanism. The ready application on existing, intact protein constructs (without specialized culture or genetic methods) suggests this C–D labeling strategy as a possible tool in protein mechanism, structure, biotechnology and medicine.


  • Open Access

    Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors

    by Jakub Stefaniak, Andrew M. Lewis, Daniel Conole, Sébastien R. G. Galan, Carole J. R. Bataille, Graham M. Wynne, M. Paola Castaldi, Thomas Lundbäck, Angela J. Russell, Kilian V. M. Huber

    Targeting the protein–protein interaction between p53 and MDM2/MDMX (MDM4) represents an attractive anticancer strategy for the treatment of p53-competent tumors. Several selective and potent MDM2 inhibitors have been developed and entered the clinic; however, the repertoire of MDMX antagonists is still limited. The arylmethylidenepyrazolinone SJ-172550 has been reported as a selective MDMX antagonist; yet, uncertainties about its mechanism of action have raised doubts about its use as a chemical probe. Here, we show that, in addition to its unclear mode of action, SJ-172550 is unstable in aqueous buffers, giving rise to side products of unknown biological activity. Using an SJ-172550-derived affinity probe, we observed promiscuous binding to cellular proteins whereas cellular thermal shift assays did not reveal a stabilizing effect on MDMX. Overall, our results raise further questions about the interpretation of data using SJ-172550 and related compounds to investigate cellular phenotypes.


  • Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7

    by Nigel. A. Swain, Dave Batchelor, Serge Beaudoin, Bruce M. Bechle, Paul A. Bradley, Alan D. Brown, Bruce Brown, Ken J. Butcher, Richard P. Butt, Mark L. Chapman, et al.

    A series of acidic diaryl ether heterocyclic sulfonamides that are potent and subtype selective NaV1.7 inhibitors is described. Optimization of early lead matter focused on removal of structural alerts, improving metabolic stability and reducing cytochrome P450 inhibition driven drug–drug interaction concerns to deliver the desired balance of preclinical in vitro properties. Concerns over nonmetabolic routes of clearance, variable clearance in preclinical species, and subsequent low confidence human pharmacokinetic predictions led to the decision to conduct a human microdose study to determine clinical pharmacokinetics. The design strategies and results from preclinical PK and clinical human microdose PK data are described leading to the discovery of the first subtype selective NaV1.7 inhibitor clinical candidate PF-05089771 (34) which binds to a site in the voltage sensing domain.


  • Posttranslational mutagenesis: A chemical strategy for exploring protein side-chain diversity

    by Tom H. Wright, Ben J. Bower, Justin M. Chalker, Gonçalo J. L. Bernardes, Rafal Wiewiora, Wai-Lung Ng, Ritu Raj, Sarah Faulkner, M. Robert J. Vallée, Anuchit Phanumartwiwath, et al.

    Radicals push proteins beyond genes: Chemically modifying proteins after their translation can expand their structural and functional roles (see the Perspective by Hofmann and Bode). Two related methods describe how to exploit free radical chemistry to form carbon-carbon bonds between amino acid residues and a selected functional group. Wright et al. added a wide range of functional groups to proteins containing dehydroalanine precursors, with borohydride mediating the radical chemistry. Yang et al. employed a similar approach, using zinc in combination with copper ions. Together, these results will be useful for introducing functionalities and labels to a wide range of proteins. Science , this issue pp. 597 and 623 ; see also p. 553